Clinical Trial Update: Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 trial of ridaforolimus (AP23573/MK-8669), an mTOR inhibitor, in patients with advanced sarcoma. The study evalua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Leiomyosarcoma
• Liposarcoma
• Osteosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Leiomyosarcoma, Liposarcoma | Phase 2 | Status: COMPLETED